438 results on '"Siccardi, Marco"'
Search Results
2. General Framework to Quantitatively Predict Pharmacokinetic Induction Drug–Drug Interactions Using In Vitro Data
3. Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
4. Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study
5. A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human
6. Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
7. Correction to: Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling
8. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
9. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.
10. Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
11. Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly
12. Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma
13. Genetic determinants of key antiretroviral pharmacokinetics
14. Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes
15. Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans.
16. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz
17. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
18. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
19. Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
20. Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study
21. UTERINE ARTERY IMPEDANCE CHANGES AFTER VERTEBRAL MANIPULATION TECHNIQUES ON THE LUMBOSACRAL JUNCTION: A RANDOMIZED CONTROLLED PILOT TRIAL IN NONPREGNANT WOMEN: O - 0114 | ORAL | PLACENTA PROBLEMS
22. Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs
23. Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV
24. Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine
25. Association of a Single-Nucleotide Polymorphism in the Pregnane X Receptor (PXR 63396C→T) with Reduced Concentrations of Unboosted Atazanavir
26. A HPLC–MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation
27. Ceftriaxone bone penetration in patients with septic non-union of the tibia
28. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach
29. LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases.
30. Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.
31. Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz
32. Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds
33. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
34. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults
35. New HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma
36. The dynamic measurement of the external pelvic obstetric diameters in shifting positions
37. The sonographic evaluation of the sub-pubic arch angle in shifting positions
38. The transverse diameter of Michaelis sacral area in shifting position could be a screening test for labor dystocia
39. Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives.
40. A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication
41. Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
42. LONG-ACTING DRUGS AND FORMULATIONS FOR THE TREATMENT AND PREVENTION OF HIV
43. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma
44. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling
45. Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation
46. Glycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia
47. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C(right arrow)T) with reduced concentrations of unboosted atazanavir
48. Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling
49. HPLC–MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients
50. Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.